Fair Pay & Worker Respect

The company has a small workforce of 13 employees.

There is no public record of any substantiated labor law or human rights violations, fines, or compliance issues in the provided articles.

Honest & Fair Business

The company has adopted a Code of Business Conduct and Ethics that provides mechanisms to report unethical or illegal conduct.

Its Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee consist of independent members. The company is subject to the U.S. Foreign Corrupt Practices Act of 1977 (FCPA) and other anti-corruption laws. However, there is no evidence of specific training frequency or effectiveness metrics for its anti-corruption policy. The company relies on contract development and manufacturing organizations (CDMOs) to produce drug candidates in accordance with FDA’s current Good Manufacturing Practices (cGMP) regulations for clinical trials, but there is no independent verification of ethical claims.

Kind to Animals

The company conducts toxicology studies for its drug candidates, such as SON-1210 and SON-080, using non-human primates (NHPs) and mice for preclinical models.

Two IND-enabling toxicology studies for SON-1210 were completed in NHPs, and a 13-week toxicology study for SON-080 was conducted on male and female cynomolgus monkeys. Preclinical studies also involved mouse melanoma models and animal models for DPN. While in vitro pharmacology studies are mentioned for affinity and binding kinetics, animal tests are used for critical safety and efficacy endpoints, indicating that alternative assays are used sporadically. The company states that no explicit animal testing policy is available, but it complies with FDA's Good Laboratory Practices (GLP) which includes animal studies. Specific animal volumes are not disclosed, but multiple studies involving NHPs (four cohorts in one study, three dose levels in another, and male and female cynomolgus monkeys in a 13-week study) and mice are detailed.

No War, No Weapons

Sonnet BioTherapeutics Holdings, Inc. is described as a clinical-stage biotechnology company focused on oncology, which is transitioning into a crypto treasury company.

The provided articles consistently state that all KPIs related to arms, defense, dual-use technology, sales to sanctioned regimes, peacebuilding, and conflict-related policies are 'Not applicable' to the company's operations. There is no evidence of any involvement in defense or arms-related activities, nor any products or services that would require such assessments.

Safe & Smart Tech

The company reported no material cyber incidents or a series of immaterial incidents requiring disclosure during the reporting period for its 10-K filing on December 16, 2025.

It maintains a cyber risk management strategy, delegates information technology and cybersecurity to a leading third-party IT consultant, stores data on the cloud, and implements standard operating procedures and training, including training employees to avoid phishing emails. The Board has ultimate oversight of cybersecurity risk, with the Interim Chief Executive Officer providing periodic updates on critical risks, initiatives, and applicable regulatory requirements. The company aims to incorporate industry best practices for companies of their size and financial strength throughout their cybersecurity program. The company's website collects contact and demographic information upon registration, uses IP addresses for diagnostics and demographics, and uses cookies. Personal information is not shared. Users can refuse cookies, which may impact access to specials or promotions. The privacy policy may be amended from time to time. The company's privacy policy does not specify data retention periods, indicating limited data minimization practices.